Gout, Uric Acid, and Coronary Artery Disease
Journal of Atherosclerosis and Thrombosis · 01.12.2025 · 32 (12) · 1471-1481
DOI: 10.5551/jat.rv22043 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Atherosclerosis and Thrombosis, erschienen am 01.12.2025. Verfasst von Takuya Nakahashi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Takaoka City Hospital. Hauptthemen laut MEDLINE: Coronary Artery Disease, Uric Acid, Gout, Hyperuricemia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Hyperuricemia, the biochemical precursor to gout, is usually defined as the theoretical limit of solubility of serum uric acid (UA) of >7.0 mg/dL. Hyperuricemia is closely associated with hypertension, diabetes mellitus, and dyslipidemia, which are well known to be related to risk factors for coronary artery disease (CAD). Furthermore, hyperuricemia has been associated with increased mortality in both the general population and individuals with cardiovascular diseases. Elevated UA in patients with CAD is accompanied by surrogate markers of atherosclerosis, including C-reactive protein, platelet activation, and endothelial dysfunction, which can contribute to possible pathogenic links between hyperuricemia and subsequent adverse cardiovascular events. Similarly, patients with gout have higher rates of cardiovascular diseases than those without it, independent of traditional cardiovascular risk factors. Gout is a disease with variable levels of inflammation, driven by deposition of monosodium urate (MSU) crystals. Recent imaging technology has revealed that deposition of MSU crystals can occur in the coronary arteries as well as the joints. However, current evidence does not support the efficacy of urate-lowering therapy on reducing cardiovascular events in patients with hyperuricemia; therefore, identifying individuals who may benefit from a sustained decrease in UA is crucial. We herein review the current understanding and future perspectives for management of hyperuricemia as a residual risk in patients with CAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Takaoka City Hospital.
- Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Science.
Zitieren
APA
Nakahashi, T., Tada, H., Sakata, K., & Takamura, M. (2025). Gout, Uric Acid, and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis, 32(12), 1471-1481. https://doi.org/10.5551/jat.rv22043
Vancouver
Nakahashi T, Tada H, Sakata K, Takamura M. Gout, Uric Acid, and Coronary Artery Disease. Journal of Atherosclerosis and Thrombosis. 2025;32(12):1471-1481. doi:10.5551/jat.rv22043
BibTeX
@article{Nakahashi2025,
author = {Nakahashi, Takuya and Tada, Hayato and Sakata, Kenji and Takamura, Masayuki},
title = {Gout, Uric Acid, and Coronary Artery Disease},
journal = {Journal of Atherosclerosis and Thrombosis},
year = {2025},
volume = {32},
number = {12},
pages = {1471--1481},
doi = {10.5551/jat.rv22043}
}
EUVIMED